Royal Bank of Canada
ANIP icon

Royal Bank of Canada’s ANI Pharmaceuticals ANIP Stock Holding History

Royal Bank of Canada’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5M Sell
213,919
-7,379
-3% -$576K ﹤0.01% 1584
2025
Q4 		$17.5M Buy
221,298
+10,594
+5% +$917K ﹤0.01% 1589
2025
Q3 		$19.3M Sell
210,704
-1,379
-0.7% -$112K ﹤0.01% 1674
2025
Q2 		$13.8M Buy
212,083
+1,693
+0.8% +$110K ﹤0.01% 1790
2025
Q1 		$14.1M Buy
210,390
+124
+0.1% +$7.41K ﹤0.01% 1544
2024
Q4 		$11.6M Sell
210,266
-221
-0.1% -$12.7K ﹤0.01% 1702
2024
Q3 		$12.6M Buy
210,487
+205,709
+4,305% +$12.5M ﹤0.01% 1644
2024
Q2 		$304K Sell
4,778
-79
-2% -$5.13K ﹤0.01% 4417
2024
Q1 		$336K Buy
4,857
+337
+7% +$20.3K ﹤0.01% 4247
2023
Q4 		$249K Buy
4,520
+1,701
+60% +$93.7K ﹤0.01% 4912
2023
Q3 		$164K Buy
2,819
+1,070
+61% +$61.7K ﹤0.01% 4978
2023
Q2 		$94K Buy
1,749
+844
+93% +$37.4K ﹤0.01% 5386
2023
Q1 		$36K Sell
905
-1,193
-57% -$50.3K ﹤0.01% 5786
2022
Q4 		$84K Buy
2,098
+1,752
+506% +$65.8K ﹤0.01% 5582
2022
Q3 		$11K Buy
346
+83
+32% +$2.84K ﹤0.01% 6372
2022
Q2 		$8K Sell
263
-601
-70% -$17.3K ﹤0.01% 6448
2022
Q1 		$24K Sell
864
-1,300
-60% -$48.5K ﹤0.01% 6499
2021
Q4 		$100K Buy
2,164
+1,092
+102% +$46.9K ﹤0.01% 5932
2021
Q3 		$35K Buy
1,072
+210
+24% +$6.53K ﹤0.01% 6357
2021
Q2 		$30K Buy
862
+300
+53% +$10.2K ﹤0.01% 6337
2021
Q1 		$20K Sell
562
-3,255
-85% -$102K ﹤0.01% 6415
2020
Q4 		$111K Sell
3,817
-6
-0.2% -$172 ﹤0.01% 5275
2020
Q3 		$108K Buy
3,823
+68
+2% +$2.02K ﹤0.01% 4924
2020
Q2 		$121K Buy
3,755
+29
+0.8% +$1.04K ﹤0.01% 4735
2020
Q1 		$152K Buy
3,726
+945
+34% +$50.3K ﹤0.01% 4506
2019
Q4 		$171K Buy
2,781
+85
+3% +$5.63K ﹤0.01% 4727
2019
Q3 		$196K Sell
2,696
-69
-2% -$5.16K ﹤0.01% 4463
2019
Q2 		$227K Buy
2,765
+1,801
+187% +$128K ﹤0.01% 4403
2019
Q1 		$68K Buy
964
+73
+8% +$4.29K ﹤0.01% 5006
2018
Q4 		$40K Sell
891
-360
-29% -$18.9K ﹤0.01% 5215
2018
Q3 		$71K Buy
1,251
+897
+253% +$54.9K ﹤0.01% 5052
2018
Q2 		$24K Buy
354
+288
+436% +$18K ﹤0.01% 5456
2018
Q1 		$4K Sell
66
-56
-46% -$3.55K ﹤0.01% 5973
2017
Q4 		$8K Sell
122
-522
-81% -$32.5K ﹤0.01% 5930
2017
Q3 		$34K Buy
644
+556
+632% +$26.5K ﹤0.01% 5639
2017
Q2 		$5K Sell
88
-125
-59% -$6.03K ﹤0.01% 6023
2017
Q1 		$10K Sell
213
-613
-74% -$34.4K ﹤0.01% 5956
2016
Q4 		$50K Buy
826
+145
+21% +$8.87K ﹤0.01% 5252
2016
Q3 		$45K Buy
681
+460
+208% +$28.8K ﹤0.01% 5204
2016
Q2 		$12K Hold
221
– – ﹤0.01% 5681
2016
Q1 		$7K Sell
221
-119
-35% -$4.04K ﹤0.01% 5829
2015
Q4 		$15K Sell
340
-1,738
-84% -$74.8K ﹤0.01% 5824
2015
Q3 		$82K Buy
2,078
+1,857
+840% +$106K ﹤0.01% 4879
2015
Q2 		$14K Hold
221
– – ﹤0.01% 5889
2015
Q1 		$14K Sell
221
-300
-58% -$18.2K ﹤0.01% 5466
2014
Q4 		$29K Buy
521
+327
+169% +$14.4K ﹤0.01% 5269
2014
Q3 		$5K Sell
194
-1,000
-84% -$30K ﹤0.01% 5640
2014
Q2 		$41K Buy
1,194
+999
+512% +$31.3K ﹤0.01% 4940
2014
Q1 		$6K Buy
195
+25
+15% +$663 ﹤0.01% 5533
2013
Q4 		$3K Buy
170
+3
+2% +$39 ﹤0.01% 5687
2013
Q3 		$2K Sell
167
-1
-0.6% -$7 ﹤0.01% 5844
2013
Q2 		$1K Buy
+168
New +$1.18K ﹤0.01% 5694

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royal Bank of Canada's ANIP Position: Q1 2026 in Review

Royal Bank of Canada reduced its ANI Pharmaceuticals (ANIP) stake by 3.3% in Q1 2026, selling an estimated $576K and leaving 213,919 shares worth $16.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

Royal Bank of Canada first reported a position in ANIP in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.3M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Royal Bank of Canada held 213,919 shares of ANI Pharmaceuticals worth $16.5M as of Q1 2026.
  • Royal Bank of Canada sold 7,379 ANI Pharmaceuticals shares in Q1 2026, an estimated $576K.
  • ANI Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1584 holding.
  • Royal Bank of Canada first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's ANI Pharmaceuticals position peaked at $19.3M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.